Gene: SLC52A3

113278
BVVLS|BVVLS1|C20orf54|RFT2|RFVT3|bA371L19.1|hRFT2
solute carrier family 52 member 3
protein-coding
20p13
Ensembl:ENSG00000101276 MIM:613350 Vega:OTTHUMG00000031647 UniprotKB:Q9NQ40
NG_027687.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.072e-1 (AD)  6.426e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6054627chr20:767191 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ACSL50.819
SLCO4A10.8
FGR0.799
IL4R0.789
FKBP50.774
TGM20.77
CDA0.768
ATOH80.756
HYAL20.753
PLA1A0.751

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CRH-0.573
CPLX3-0.521
HAPLN1-0.515
VWC2-0.495
KIT-0.492
PRLHR-0.486
PTHLH-0.485
PNOC-0.485
IGF1-0.483
CRHBP-0.482

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
D000143AcidsAcids promotes the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D020106AcrylamideAcrylamide results in increased expression of SLC52A3 mRNA28959563
D000584AmilorideAmiloride inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of SLC52A3 mRNA24449571
D001280AtrazineAtrazine results in increased expression of SLC52A3 mRNA25929836
D001280AtrazineAtrazine results in increased expression of SLC52A3 mRNA22378314
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of SLC52A3 mRNA26496021
C006780bisphenol Abisphenol A affects the expression of SLC52A3 mRNA25181051
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of SLC52A3 mRNA26496021
C016366dibenzothiophenedibenzothiophene results in increased expression of SLC52A3 mRNA23656968
C118739entinostatentinostat results in increased expression of SLC52A3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
D005182Flavin-Adenine DinucleotideFlavin-Adenine Dinucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D005486Flavin MononucleotideFlavin Mononucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
C039281furanfuran results in increased methylation of SLC52A3 gene22079235
C010974glyphosateglyphosate results in increased expression of SLC52A3 mRNA25636363
D017313FenretinideFenretinide results in increased expression of SLC52A3 mRNA28973697
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of SLC52A3 mRNA24796395
C001922lumiflavinlumiflavin inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of SLC52A3 mRNA26011545
C406082monomethylarsonous acid[monomethylarsonous acid affects the acetylation of HIST3H3 protein] which affects the methylation of SLC52A3 promoter18448484
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of SLC52A3 mRNA"25554681
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of SLC52A3 mRNA26272509
D010936Plant ExtractsPlant Extracts results in decreased expression of SLC52A3 mRNA23557933
C005556propionaldehydepropionaldehyde results in increased expression of SLC52A3 mRNA26079696
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of SLC52A3 mRNA25895662
D012834SilverSilver results in increased expression of SLC52A3 mRNA27131904
C017947sodium arsenite[sodium arsenite affects the acetylation of HIST3H3 protein] which affects the methylation of SLC52A3 promoter18448484
C009495titanium dioxidetitanium dioxide results in decreased expression of SLC52A3 mRNA23557971
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SLC52A3 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SLC52A3 mRNA23179753|2352703
C029297vinylidene chloridevinylidene chloride results in increased expression of SLC52A3 mRNA26682919
D012256RiboflavinAcids promotes the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D012256RiboflavinAmiloride inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D012256RiboflavinFlavin-Adenine Dinucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D012256RiboflavinFlavin Mononucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D012256Riboflavinlumiflavin inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin]19122205
D012256RiboflavinSLC52A3 protein results in increased transport of Riboflavin19122205

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0032217riboflavin transmembrane transporter activity-IDA20463145  
GO:0032217riboflavin transmembrane transporter activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006771riboflavin metabolic process-TAS-  
GO:0007605sensory perception of sound-IMP20206331  
GO:0032218riboflavin transport-IDA20463145  22273710  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-IDA22273710  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IDA20463145  
GO:0016324apical plasma membrane-IEA-  
KEGG ID KEGG Term
hsa04977Vitamin digestion and absorption
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-196843Vitamin B2 (riboflavin) metabolismTAS
R-HSA-196849Metabolism of water-soluble vitamins and cofactorsTAS
R-HSA-196854Metabolism of vitamins and cofactorsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27600099Decreased risk of developing cancer in subjects carrying SLC52A3 rs13042395 polymorphism: proof from a meta-analysis. (2016 Oct)Li JBiomark Med